| Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. | |
| | |
MedLine Citation:
|
PMID: 16524863 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To report 3 cases of bisphosphonate-induced hypocalcemia and review the relevant literature. METHODS: We present the clinical and laboratory findings in 3 cases of bisphosphonate-induced hypocalcemia, and discuss the pathophysiologic mechanisms and the pertinent literature. RESULTS: In our first patient (case 1), symptomatic hypocalcemia developed after intravenous administration of pamidronate for management of multiple myeloma. He had vitamin D insufficiency and impaired renal function at the time of pamidronate therapy. Our second patient (case 2) presented with symptomatic hypocalcemia 12 weeks after initiation of alendronate therapy for osteoporosis. Her serum 25-hydroxyvitamin D level was low (3 ng/mL), attributable to a combination of poor vitamin D intake, limited exposure to sunlight, use of phenytoin, and previous intestinal resections. In our third patient (case 3), hypocalcemia developed on 2 different occasions, each episode occurring after intravenous administration of pamidronate for hypercalcemia of malignancy. All 3 patients had underlying conditions that impaired the homeostatic response to bisphosphonates and contributed to the severe hypocalcemia. Review of published reports on symptomatic bisphosphonate-induced hypocalcemia disclosed that hypocalcemia develops in patients with unrecognized hypoparathyroidism, impaired renal function, or vitamin D deficiency. Overall, the rate of the development of hypocalcemia was related to the potency of the bisphosphonate administered. CONCLUSION: The increasing use of bisphosphonates and the introduction of more potent agents impose a considerable risk for bisphosphonate-induced hypocalcemia in a substantial number of patients. Greater awareness of this complication, a better understanding of the underlying mechanisms, and proper assessment of patients in whom bisphosphonate therapy is contemplated should reduce the frequency of occurrence of this potentially life-threatening complication. |
| | |
Authors:
|
Naim M Maalouf; Howard J Heller; Clarita V Odvina; Peter J Kim; Khashayar Sakhaee |
Related Documents
:
|
17206473 - Radiation induced peripheral nerve tumors: case series and review of the literature. 9483263 - Neuroleptic-induced laryngeal dystonia can mimic anaphylaxis. 11733893 - Isolated subscapularis tear from minimal trauma in a recreational athlete: a case report. |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 12 ISSN: 1530-891X ISO Abbreviation: Endocr Pract Publication Date: 2006 Jan-Feb |
Date Detail:
|
Created Date: 2006-03-09 Completed Date: 2006-05-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 48-53 Citation Subset: IM |
Affiliation:
|
Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-8885, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Bone Density Conservation Agents / adverse effects*, therapeutic use Calcium Compounds / therapeutic use Diphosphonates / adverse effects*, therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Humans Hypocalcemia / chemically induced*, drug therapy, physiopathology Male Middle Aged Osteoporosis / drug therapy, prevention & control Risk Assessment Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Calcium Compounds; 0/Diphosphonates |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and cr...
Next Document: Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and re...